Stoke Therapeutics Inc (STOK) Stock Price, Quote & News

Company Profile

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 430 8200

Website: www.stoketherapeutics.com

Address:

45 Wiggins Avenue, Bedford, United States

NorthStarStats Apr. 8 at 8:39 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $FRT Score 100, $ANET Score 98, $ENTG Score 98, $STOK Score 98, $ASND Score 98

0 · Reply

Doozio Mar. 31 at 2:01 PM

$XBI list of biotech $STOK s that $AUPH to $ASND after this 🐑 correction.

0 · Reply

StocktwitsEarnings Mar. 26 at 7:00 PM

$STOK Q4 '25 Earnings Results & Recap Stoke Therapeutics expects its cash, cash equivalents, and marketable securities of approximately $390.9M as of December 31, 2025, will fund operations into 2028, and anticipates pivotal Phase 3 data for zorevunersen in mid-2027.

0 · Reply

ObeCalp Mar. 26 at 5:59 PM

$STOK Of course, I buy when green... and shortly after it goes red. Yay, me.

0 · Reply

Quantumup Mar. 20 at 11:53 AM

Canaccord Genuity⬆️ $STOK's PT to $60 from $36 and reiterated at a Buy rating. $BIIB $PRAX DRUG UCBJY JAZZ HLUBF HLBBF Here's what Canaccord Genuity had to say in its note to investors: https://x.com/Quantumup1/status/2034960529656029691?s=20

0 · Reply

danaos Mar. 19 at 1:04 AM

$STOK Price Target $25 (shortterm)

0 · Reply

erevnon Mar. 18 at 2:25 PM

Wedbush maintains Stoke Therapeutics $STOK at Outperform and raises the price target from $36 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Mar. 17 at 12:13 PM

Needham maintains Stoke Therapeutics $STOK at Buy and raises the price target from $35 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

LadsAndGents Mar. 9 at 2:21 PM

$STOK why don’t just buy this out

0 · Reply

janed102 Mar. 5 at 8:24 AM

$STOK https://www.nejm.org/doi/full/10.1056/NEJMoa2506295

0 · Reply

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 4:01 PM EDT - 1 day ago

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

Mar 17, 2026, 5:12 PM EDT - 22 days ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mar 4, 2026, 5:06 PM EST - 5 weeks ago

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

BIIB

Feb 24, 2026, 4:01 PM EST - 6 weeks ago

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 7:30 AM EST - 2 months ago

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

Feb 4, 2026, 4:01 PM EST - 2 months ago

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 27, 2026, 2:05 PM EST - 2 months ago

Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA

Jan 11, 2026, 2:00 PM EST - 3 months ago

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

BIIB

Jan 6, 2026, 4:01 PM EST - 3 months ago

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 9:00 AM EST - 4 months ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

BIIB

Dec 1, 2025, 7:30 AM EST - 4 months ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

BIIB

Nov 17, 2025, 7:30 AM EST - 5 months ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

BIIB

Nov 5, 2025, 4:01 PM EST - 5 months ago

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 4:01 PM EST - 5 months ago

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 30, 2025, 4:30 PM EDT - 5 months ago

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

Oct 20, 2025, 7:30 AM EDT - 6 months ago

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

Oct 9, 2025, 4:30 PM EDT - 6 months ago

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

BIIB

Oct 6, 2025, 7:30 AM EDT - 6 months ago

Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BIIB

Aug 28, 2025, 4:30 PM EDT - 7 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

Aug 25, 2025, 7:00 AM EDT - 8 months ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

BIIB

Aug 12, 2025, 4:01 PM EDT - 8 months ago

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 11, 2025, 7:00 AM EDT - 8 months ago

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

BIIB

Aug 7, 2025, 7:00 AM EDT - 8 months ago

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

Aug 6, 2025, 4:30 PM EDT - 8 months ago

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 4:30 PM EDT - 9 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 7:00 AM EDT - 9 months ago

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jul 10, 2025, 7:00 AM EDT - 9 months ago

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

May 29, 2025, 7:30 AM EDT - 11 months ago

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 11 months ago

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 4:30 PM EDT - 1 year ago

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 18, 2025, 12:56 PM EDT - 1 year ago

Stoke Therapeutics Stock Slips as CEO Steps Down

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 6:58 AM EDT - 1 year ago

Stoke Therapeutics Announces CEO Transition

Feb 26, 2025, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Feb 18, 2025, 8:46 AM EST - 1 year ago

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

BIIB

$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

Feb 18, 2025, 8:00 AM EST - 1 year ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

BIIB

Jan 8, 2025, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 1 year ago

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Jan 6, 2025, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Dec 6, 2024, 12:00 PM EST - 1 year ago

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 1 year ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB PRAX WGS

Dec 4, 2024, 7:00 AM EST - 1 year ago

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Dec 2, 2024, 8:00 AM EST - 1 year ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Nov 5, 2024, 7:00 AM EST - 1 year ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

NorthStarStats Apr. 8 at 8:39 PM

0 · Reply

Doozio Mar. 31 at 2:01 PM

$XBI list of biotech $STOK s that $AUPH to $ASND after this 🐑 correction.

0 · Reply

StocktwitsEarnings Mar. 26 at 7:00 PM

0 · Reply

ObeCalp Mar. 26 at 5:59 PM

$STOK Of course, I buy when green... and shortly after it goes red. Yay, me.

0 · Reply

Quantumup Mar. 20 at 11:53 AM

0 · Reply

danaos Mar. 19 at 1:04 AM

$STOK Price Target $25 (shortterm)

0 · Reply

erevnon Mar. 18 at 2:25 PM

Wedbush maintains Stoke Therapeutics $STOK at Outperform and raises the price target from $36 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Mar. 17 at 12:13 PM

Needham maintains Stoke Therapeutics $STOK at Buy and raises the price target from $35 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

LadsAndGents Mar. 9 at 2:21 PM

$STOK why don’t just buy this out

0 · Reply

janed102 Mar. 5 at 8:24 AM

$STOK https://www.nejm.org/doi/full/10.1056/NEJMoa2506295

0 · Reply

janed102 Mar. 5 at 8:22 AM

$STOK https://www.bbc.co.uk/news/articles/c3rzj9jy9e8o

0 · Reply

OfficialStocktwitsUser Mar. 2 at 8:37 PM

$STOK RSI: 77.18, MACD: 1.4185 Vol: 2.14, MA20: 33.36, MA50: 32.12 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MK724 Mar. 2 at 5:09 PM

$STOK what’s the next resistance?

0 · Reply

erevnon Feb. 24 at 12:42 PM

Wolfe Research initiates coverage on Stoke Therapeutics $STOK at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

BillionerOfKing Feb. 18 at 6:02 PM

$STOK Current Stock Price: $31.32 Contracts to trade: $30.0 STOK Feb 20 2026 Call Entry: $0.25 Exit: $0.41 ROI: 63% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ValuationExpert Feb. 18 at 4:38 PM

$STOK Stoke Therapeutics focuses on RNA-based therapies. Clinical data drives valuation. Cash runway supports development.

0 · Reply

ClinicalTrialsDaily Feb. 12 at 7:13 PM

$STOK Clinical pivot point: STK-002 OSPREY trial vs SOC $SANN (Idebenone). Differentiation: 1. SOC = Metabolic bandaid (Oral) 2. STK-002 = Genetic fix (IVT ASO) Key Risk: Ocular inflammation (Endophthalmitis). ADOA is slowly progressive, so safety bar is higher than LHON. Structural RNFL endpoints > VA for early signal. Watch Q4 2026 data. $PYC Read more: www.clinicaltrialsdaily.com/stk-002-adoa-disease-modifying-potential/

0 · Reply

TheTradeXchange Feb. 11 at 12:30 PM

$STOK Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

0 · Reply

BillionerOfKing Feb. 9 at 12:41 PM

$STOK Current Stock Price: $32.37 Contracts to trade: $30.0 STOK Feb 20 2026 Call Entry: $3.12 Exit: $4.31 ROI: 38% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

notreload_ai Feb. 5 at 1:57 PM

Guggenheim initiates coverage on $STOK , highlighting Zorevunersen’s potential as a disease-modifying treatment for Dravet syndrome and projecting $2.5B peak sales. https://notreload.xyz/guggenheim-starts-coverage-on-stoke-therapeutics-with-buy-rating-and-60-target/

0 · Reply

Market Cap	2.00B
Revenue (ttm)	184.42M
Net Income (ttm)	-6.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3.74%
Debt to Equity Ratio	0.00

Volume	1,245,900
Avg Vol	792,994
Day's Range	N/A - N/A
Shares Out	59.15M
Stochastic %K	75%
Beta	1.22
Analysts	Strong Sell
Price Target	$45.07